new
   Indications for Siponimod (Mayzent)
503
Oct 30, 2025

Siponimod (Mayzent) is a sphingosine 1-phosphate (S1P) receptor modulator used for the treatment of relapsing forms of multiple sclerosis (MS).

Indications for Siponimod (Mayzent)

Primary Indications

Siponimod is indicated for the treatment of adult patients with the following relapsing forms of multiple sclerosis (MS).

Clinically Isolated Syndrome (CIS): For patients who experience a first demyelinating event and are at high risk of relapse.

Relapsing-Remitting Multiple Sclerosis (RRMS): For reducing the frequency of disease relapses and delaying the progression of disability.

Active Secondary Progressive Multiple Sclerosis (aSPMS): For patients with secondary progressive disease who have evidence of disease activity (such as relapses or MRI lesions).

Dosage Forms, Strengths and Properties of Siponimod (Mayzent)

Dosage Forms and Strengths

0.25mg tablets: Light red, round, biconvex film-coated tablets with beveled edges. One side is engraved with "T", and the other side is blank.

1mg tablets: Purple-white, round, biconvex film-coated tablets with beveled edges. One side is engraved with "L", and the other side is blank.

2mg tablets: Light yellow, round, biconvex film-coated tablets with beveled edges. One side is engraved with "II", and the other side is blank.

Excipient Ingredients

The tablet core contains microcrystalline cellulose, crospovidone, etc.

The film coating contains polyvinyl alcohol, titanium dioxide, and iron oxide colorants (red and black iron oxides for 0.25mg and 1mg tablets; red and yellow iron oxides for 2mg tablets), etc.

Administration Method

Swallow the tablet whole. Do not split, crush, or chew it.

A 5-day dose escalation (starting at 0.25mg/day and gradually increasing to 2mg/day) is required to reduce the risk of cardiac adverse reactions.

Storage Methods for Siponimod (Mayzent)

Unopened Packaging

Store under refrigeration at 2°C–8°C (36°F–46°F).

After being dispensed to patients by the pharmacy, it can be stored at room temperature (20°C–25°C / 68°F–77°F) for a maximum of 3 months.

Opened Packaging

Bottled tablets: After opening, they can be stored at room temperature for 3 months, no refrigeration required.

Initiation pack (blister cards): After opening, the original calendarized blister packaging must be retained, and the product should be stored at room temperature for no more than 3 months.

Precautions

Avoid direct sunlight and humid environments.

Keep out of the reach of children.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Adverse Reactions of Pralsetinib (Gavreto)

Pralsetinib (Gavreto) is a targeted therapy for RET fusion-positive tumors. While delivering therapeutic benefits to...

Monday, December 22nd, 2025, 09:44
What Are the Precautions for Pralsetinib (Gavreto) Administration?

Pralsetinib (Gavreto) is a new-generation highly selective RET inhibitor, offering a breakthrough treatment option...

Monday, December 22nd, 2025, 09:41
Dosage and Administration, Recommended Dose of Pralsetinib (Gavreto)

Pralsetinib (Gavreto) is a kinase inhibitor targeting RET gene fusions, and it demonstrates significant value in the...

Monday, December 22nd, 2025, 09:34
What Are the Indications for Pralsetinib (Gavreto)?

Pralsetinib (Gavreto) is an oral kinase inhibitor primarily indicated for the treatment of specific malignant tumors...

Monday, December 22nd, 2025, 09:26
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved